Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany

View through CrossRef
Background and aimsIn the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor. In addition, data from patients with atherosclerotic cardiovascular disease (ASCVD) in diverse regional backgrounds, including the understudied Brandenburg cohort, and various healthcare statuses remain insufficient.MethodsIn this WalkByLab study, Lp(a) levels were monitored in a non-metropolitan cohort (n = 850) in Brandenburg, Germany, comprising 533 patients at high cardiovascular risk and 317 healthy controls. Patients underwent a comprehensive angiological screening, which included blood serum analysis, assessment of medical and family history, cardiovascular risk, and disease status, and evaluation of lifestyle and quality of life. All parameters were evaluated with regard to two groups based on Lp(a) levels: low (<50 mg/dl) and high (≥50 mg/dl).ResultsBrandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.2% vs. 14.8%, p = 0.001). Logistic regression analysis with different characteristics revealed that Lp(a) was an independent risk factor significantly associated with ASCVD (OR 2.26, 95% CI 1.32–3.95, p = 0.003). The high-Lp(a) group showed a higher proportion of patients with coronary artery disease, peripheral artery disease, or cerebrovascular disease compared to the low-Lp(a) group (50% vs. 36.8%; 57.7% vs. 45.8%; 17.6% vs. 9.2%; p = 0.004); also, a higher percentage of patients in the high-Lp(a) group had heart failure (72.8% vs. 53.2%, p = 0.014) and myocardial infarction (24.7% vs. 13.9%, p = 0.001). The high-Lp(a) group exhibited higher rates of statins (63.1% vs. 50.4%, p = 0.003), ezetimibe (14.8% vs. 5.5.%, p = 0.001), and beta-blockers (55.7% vs. 40.7%, p = 0.001) use. Lp(a) levels were found to be independent of physical activity or smoking behavior and did not change over time (12 months).ConclusionsOur study highlights the significance of elevated Lp(a) levels in Brandenburg cardiovascular patients and identifies them as an independent risk factor for ASCVD, which has implications for addressing cardiovascular health of non-metropolitan populations.
Title: Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany
Description:
Background and aimsIn the non-metropolitan region of Brandenburg (Germany), which is characterized by high rates of cardiovascular diseases and underserved medical care, there is a lack of awareness regarding lipoprotein(a) [Lp(a)] as a risk factor.
In addition, data from patients with atherosclerotic cardiovascular disease (ASCVD) in diverse regional backgrounds, including the understudied Brandenburg cohort, and various healthcare statuses remain insufficient.
MethodsIn this WalkByLab study, Lp(a) levels were monitored in a non-metropolitan cohort (n = 850) in Brandenburg, Germany, comprising 533 patients at high cardiovascular risk and 317 healthy controls.
Patients underwent a comprehensive angiological screening, which included blood serum analysis, assessment of medical and family history, cardiovascular risk, and disease status, and evaluation of lifestyle and quality of life.
All parameters were evaluated with regard to two groups based on Lp(a) levels: low (<50 mg/dl) and high (≥50 mg/dl).
ResultsBrandenburg patients with cardiovascular diseases showed higher Lp(a) levels than healthy controls (24.
2% vs.
14.
8%, p = 0.
001).
Logistic regression analysis with different characteristics revealed that Lp(a) was an independent risk factor significantly associated with ASCVD (OR 2.
26, 95% CI 1.
32–3.
95, p = 0.
003).
The high-Lp(a) group showed a higher proportion of patients with coronary artery disease, peripheral artery disease, or cerebrovascular disease compared to the low-Lp(a) group (50% vs.
36.
8%; 57.
7% vs.
45.
8%; 17.
6% vs.
9.
2%; p = 0.
004); also, a higher percentage of patients in the high-Lp(a) group had heart failure (72.
8% vs.
53.
2%, p = 0.
014) and myocardial infarction (24.
7% vs.
13.
9%, p = 0.
001).
The high-Lp(a) group exhibited higher rates of statins (63.
1% vs.
50.
4%, p = 0.
003), ezetimibe (14.
8% vs.
5.
5.
%, p = 0.
001), and beta-blockers (55.
7% vs.
40.
7%, p = 0.
001) use.
Lp(a) levels were found to be independent of physical activity or smoking behavior and did not change over time (12 months).
ConclusionsOur study highlights the significance of elevated Lp(a) levels in Brandenburg cardiovascular patients and identifies them as an independent risk factor for ASCVD, which has implications for addressing cardiovascular health of non-metropolitan populations.

Related Results

Beyond traditional lipid markers: why lipoprotein(a) screening matters
Beyond traditional lipid markers: why lipoprotein(a) screening matters
Aim: To assess the correlation between lipoprotein(a) levels and traditional lipid profile markers in statin-naive men and women without established atherosclerotic cardiovascular ...
Oral Muvalaplin for Lowering of Lipoprotein(a)
Oral Muvalaplin for Lowering of Lipoprotein(a)
ImportanceMuvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effe...
GW24-e2249 One-year cardiovascular event rates in patients with atherothrombotic disease in China
GW24-e2249 One-year cardiovascular event rates in patients with atherothrombotic disease in China
Objectives We sought to assess the risk profile, management and subsequent 1-year cardiovascular (CV) event rates in Chinese patients who had a history of establi...
Association between dog and cat ownership with cardiovascular disease: A systematic review and meta-analysis
Association between dog and cat ownership with cardiovascular disease: A systematic review and meta-analysis
Background: Numerous studies have described the correlation of pet ownership with cardiovascular diseases, with dog and cat ownership emerging as the predominant forms of pet compa...
MICROLBUMINURIA AS A MARKER FOR ATHEROSCLEROTIC DISEASE
MICROLBUMINURIA AS A MARKER FOR ATHEROSCLEROTIC DISEASE
Objective: The objective of this study is to see whether microalbuminuria is an independent associated risk factor for atherosclerotic cardiovascular disease in non-diabetic patien...
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
The Effects of Xanthine Oxidase Inhibitors on the Management of Cardiovascular Diseases
Cardiovascular diseases (CVDs) are the fastest-growing cause of death around the world, and atherosclerosis plays a major role in the etiology of CVDs. The most recent figures show...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct Introduction Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Protein S100A8 in atherosclerotic lesions in humans
Protein S100A8 in atherosclerotic lesions in humans
Introduction. In the pathogenesis of atherosclerosis, a change in the content of different proteins in S100 protein family may play an important role in the formation of atheroscle...

Back to Top